Bioventus/BVS

$4.57

-4.98%
-
1D1W1MYTD1YMAX

About Bioventus

Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.

Ticker

BVS

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Robert Claypoole

Employees

970

Headquarters

Durham, United States

Bioventus Metrics

BasicAdvanced
$393.45M
Market cap
-
P/E ratio
-$2.93
EPS
-
Beta
-
Dividend rate
$393.45M
$6.08
$0.86
138.94K
1.551
0.944
211.252
222.283
0.37%
-14.34%
-47.06%
-18.91%
0.783
2.205
-2.7%
-33.25%
14.61%

What the Analysts think about Bioventus

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
75.05% upside
High $9.00
Low $7.00
$4.57
Current price
$8.00
Average price target

Bioventus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-6.04% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$120.7M
-11.9%
Net income
$-7.3M
102.78%
Profit margin
-6.04%
130.53%

Bioventus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 250%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.26
$0.14
$0.05
$0.07
-
Expected
-$0.15
$0.00
-$0.02
$0.02
-$0.08
Surprise
73.33%
∞%
-350%
250%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Bioventus stock?

Bioventus (BVS) has a market cap of $393.45M as of April 13, 2024.

What is the P/E ratio for Bioventus stock?

The price to earnings (P/E) ratio for Bioventus (BVS) stock is 0 as of April 13, 2024.

Does Bioventus stock pay dividends?

No, Bioventus (BVS) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Bioventus dividend payment date?

Bioventus (BVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Bioventus?

Bioventus (BVS) does not currently have a Beta indicator.

What is the Bioventus stock price target?

The target price for Bioventus (BVS) stock is $8, which is 75.05% above the current price of $4.57. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Bioventus stock

Buy or sell Bioventus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing